FDA encourages decentralized trials with new guidance

Companies looking to execute decentralized clinical trials should watch out for data variability and precision as information comes in from patients’ homes or local healthcare facilities, according to new FDA guidance. But the agency is otherwise keen to see more of these studies to help boost diversity in clinical research.